Theriva Biologics Financials - Benzinga

Theriva Biologics Inc

TOVXAMEX

Trade with Public

Trade with Public

$0.2308

N/A

In chiusura: Sep 22, 5:00 PM EST

Panoramica Notizie Previsioni utili Eventi Obiettivi di prezzoDati finanziariSentiment Azionariato Confronta Rapporto azionario

Theriva Biologics Financials

Theriva Biologics (TOVX) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Theriva Biologics Q2 EPS $(0.07) Misses $(0.05) Estimate

Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(0.07) per share which missed the analyst consensus estimate of $(0.05) by 40 percent. This is a 96.37 percent increase over losses of $(1.93) per share from

Benzinga Newsdesk

PRO
Theriva Biologics Q1 EPS $(0.05), Inline

Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(0.05) per share which met the analyst consensus estimate. This is a 96.77 percent increase over losses of $(1.55) per share from the same period last year.

Benzinga Newsdesk

PRO
Theriva Biologics Q4 EPS $(0.12) Beats $(0.50) Estimate

Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.50) by 76.2 percent. This is a 92.52 percent increase over losses of $(1.59) per share from

Benzinga Newsdesk

PRO
Theriva Biologics Q3 EPS $(0.45) Beats $(1.13) Estimate

Theriva Biologics (AMEX:TOVX) reported quarterly losses of $(0.45) per share which beat the analyst consensus estimate of $(1.13) by 60.18 percent. This is a 93.39 percent increase over losses of $(6.81) per share from

Benzinga Newsdesk

Dow Dips Over 100 Points; US Crude Oil Inventories Surge

Avi Kapoor

Dow Surges Over 100 Points; Charles Schwab Posts Upbeat Earnings

Avi Kapoor

© 2026 Benzinga | All Rights Reserved